Maxcyte (MXCT) Enterprise Value (2020 - 2025)
Historic Enterprise Value for Maxcyte (MXCT) over the last 6 years, with Q3 2025 value amounting to -$105.7 million.
- Maxcyte's Enterprise Value rose 3127.05% to -$105.7 million in Q3 2025 from the same period last year, while for Sep 2025 it was -$105.7 million, marking a year-over-year increase of 3127.05%. This contributed to the annual value of -$154.5 million for FY2024, which is 820.38% up from last year.
- Per Maxcyte's latest filing, its Enterprise Value stood at -$105.7 million for Q3 2025, which was up 3127.05% from -$126.6 million recorded in Q2 2025.
- Maxcyte's 5-year Enterprise Value high stood at -$73.4 million for Q2 2021, and its period low was -$255.9 million during Q3 2021.
- Over the past 5 years, Maxcyte's median Enterprise Value value was -$179.3 million (recorded in 2023), while the average stood at -$184.7 million.
- In the last 5 years, Maxcyte's Enterprise Value tumbled by 63367.09% in 2021 and then surged by 3127.05% in 2025.
- Over the past 5 years, Maxcyte's Enterprise Value (Quarter) stood at -$255.0 million in 2021, then increased by 10.86% to -$227.3 million in 2022, then grew by 25.98% to -$168.3 million in 2023, then grew by 8.2% to -$154.5 million in 2024, then soared by 31.56% to -$105.7 million in 2025.
- Its Enterprise Value was -$105.7 million in Q3 2025, compared to -$126.6 million in Q2 2025 and -$138.3 million in Q1 2025.